leadf
logo-loader
RNS
viewNovacyt SA

Novacyt S.A. - Director/PDMR Shareholding

RNS Number : 7952F
Novacyt S.A.
18 November 2020
 

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Director/PDMR Shareholding

 

Paris, France and Camberley, UK - 18 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 12 November 2020, Anouska Penny-Gibson, a person closely associated (PCA) to Steve Gibson, a PDMR of Novacyt, acquired 697 ordinary shares of €1/15 each in the Company at an average price of £8.59 per share.  The resultant beneficial shareholding of Mr. Gibson is 9,116 ordinary shares representing 0.01% of the Company's issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 

Anouska Penny-Gibson

 

2.

Reason for the Notification

a)

Position/status

PCA to Steve Gibson (PDMR)

 

b)

Initial notification/ Amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Novacyt S.A.

b)

LEI

213800BWAC2BF295EG28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of €1/15 each

 


Identification code

FR0010397232

b)

Nature of the transaction

Acquisition of Ordinary Shares

 

c)

Price(s) and volume(s)

 

Price

Volume

£8.88

111

£8.57

231

£8.41

355

d)

Aggregated information:

· Aggregated volume

· Price

 

Price

Volume

£8.59

697

 

 

e)

Date of the transaction

 

12 November 2020

f)

Place of the transaction

London Stock Exchange, AIM

 

 

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com 

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests.  Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing.  The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide.  The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPGWGGUPUGRR

Quick facts: Novacyt SA

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read